Madrigal製藥 MDGL 深 滬
等待開盤 11-05 09:30:00 美东时间
444.64
+32.290
+7.83%
華盛通- 最 高469.95
- 今 開406.22
- 成交量 124.91万股
- 最 低 405.00
- 昨 收 412.35
- 總市值 99.11亿
- 52周最高 469.95
- 市盈率 靜 --
- 換手率 5.60%
- 52周最低 265.00
- 委 比 95.36%
- 總股本 2228.90万
- 歷史最高 469.95
- 量 比 2.78
- 振 幅 15.75%
- 歷史最低 5.25
- 每 手 1
- 風險率 51.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
- Third-quarter 2025 net sales of Rezdiffra: $287.3 million - Over 29,500 patients on Rezdiffra as of September 30, 2025 - Global licensing agreement with CSPC Pharma for oral GLP-1 - New patent for Rezdiffra providing protection into 2045 - Launched Rezdiffra in Germany following EU approval - Cash, cash equivalents, restricted cash, and marketable securities: $1.1 billion - Annualized sales exceeding $1 billion, positioning Rezdiffr...
11-04 12:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast
Madrigal Pharmaceuticals (NASDAQ:MDGL) is set to give its latest quarterly earn...
11-04 01:02
Madrigal Pharmaceuticals Announces Multiple MASH And Rezdiffra Data Presentations At The AASLD's The Liver Meeting Nov 7–11, 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the
10-28 20:13
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Madrigal Pharmaceuticals announced multiple presentations at the 2025 AASLD Liver Meeting highlighting Rezdiffra data in MASH patients. Key highlights include two oral presentations on biomarkers, imaging, and quality-of-life data from the Phase 3 MAESTRO-NAFLD-1 trial, as well as a Poster of Distinction examining the impact of Rezdiffra interruption. Other posters explore real-world experience with Rezdiffra and the clinical burden of MASH. Rezd...
10-28 12:00
嘉实标普生物科技ETF（QDII）三季报解读：净值增长19.51% 净申购4900万份
主要财务指标：本期利润2.52亿元 期末净值15.23亿元 报告期内（2025年7月1日-9月30日），基金主要财务指标表现如下：本期已实现收益5379.2...
10-28 00:03
易方达标普生物科技LOF三季报解读：C类份额激增309.9% 净值增长率18.38%
主要财务指标：AC类利润双增长 期末净值A类1.4368元 报告期内，易方达标普生物科技指数（QDII-LOF）A类和C类份额均实现盈利，期末净值保持稳定。...
10-27 22:43
1100亿美元！生物医药并购潮重启
作者｜YY 01 重启的并购周期 2025年，全球生物医药行业的并购活动出现显著回升。据统计，截至10月中旬，制药与生物科技领域共计宣布超过400起交易，累计金...
10-26 07:31
Why Is Viking Therapeutics Stock Rising Today?
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.
10-24 00:32
